[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
Identifieur interne : 000A53 ( Ncbi/Checkpoint ); précédent : 000A52; suivant : 000A54[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
Auteurs :Source :
- Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases [ 1001-0939 ] ; 2020.
Abstract
At the end of December 2019, a novel coronavirus (COVID-19) caused an outbreak in Wuhan, and has quickly spread to all provinces in China and 26 other countries around the world, leading to a serious situation for epidemic prevention. So far, there is still no specific medicine. Previous studies have shown that chloroquine phosphate (chloroquine) had a wide range of antiviral effects, including anti-coronavirus. Here we found that treating the patients diagnosed as novel coronavirus pneumonia with chloroquine might improve the success rate of treatment, shorten hospital stay and improve patient outcome. In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine.
DOI: 10.3760/cma.j.issn.1001-0939.2020.0019
PubMed: 32075365
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000B08
- to stream PubMed, to step Curation: 000B08
- to stream PubMed, to step Checkpoint: 000073
- to stream Ncbi, to step Merge: 000A53
- to stream Ncbi, to step Curation: 000A53
Links to Exploration step
pubmed:32075365Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].</title>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32075365</idno>
<idno type="pmid">32075365</idno>
<idno type="doi">10.3760/cma.j.issn.1001-0939.2020.0019</idno>
<idno type="wicri:Area/PubMed/Corpus">000B08</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B08</idno>
<idno type="wicri:Area/PubMed/Curation">000B08</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B08</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000073</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000073</idno>
<idno type="wicri:Area/Ncbi/Merge">000A53</idno>
<idno type="wicri:Area/Ncbi/Curation">000A53</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000A53</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].</title>
</analytic>
<series><title level="j">Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases</title>
<idno type="ISSN">1001-0939</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">At the end of December 2019, a novel coronavirus (COVID-19) caused an outbreak in Wuhan, and has quickly spread to all provinces in China and 26 other countries around the world, leading to a serious situation for epidemic prevention. So far, there is still no specific medicine. Previous studies have shown that chloroquine phosphate (chloroquine) had a wide range of antiviral effects, including anti-coronavirus. Here we found that treating the patients diagnosed as novel coronavirus pneumonia with chloroquine might improve the success rate of treatment, shorten hospital stay and improve patient outcome. In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine.</div>
</front>
</TEI>
<affiliations><list></list>
<tree></tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A53 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 000A53 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= CovidV2 |flux= Ncbi |étape= Checkpoint |type= RBID |clé= pubmed:32075365 |texte= [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:32075365" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a CovidV2
This area was generated with Dilib version V0.6.33. |